Zenocutuzumab-zbco

Zenocutuzumab Gains FDA Orphan Drug Status in CCA

WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...

By cGxPwire Editor
February 6, 2026

Bio-Pharma

Zenocutuzumab-zbco Earns FDA Breakthrough Therapy Status for NRG1+ Cholangiocarcinoma

LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...

By cGxPwire Editor
October 23, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Zenocutuzumab-zbco

Zenocutuzumab Gains FDA Orphan Drug Status in CCA

Zenocutuzumab-zbco Earns FDA Breakthrough Therapy Status for NRG1+ Cholangiocarcinoma